BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Finnzymes Instruments Oy Establishes New Sister Company, BioInnovations Oy


1/12/2007 2:47:27 PM

Finnzymes Instruments enters into a joint venture with Bridge Biosciences Corporation to form a new company called BioInnovations Oy. In exchange for monetary considerations, Finnzymes Instruments becomes the majority shareholder in this new entity.

The deal transfers all physical assets, patents and expertise from the PCR plastics business of Bridge Biosciences to BioInnovations. Pekka Mattila, CEO of Finnzymes Instruments commented on the joint venture: “This partnership will secure unique intellectual property related to the design and manufacture of vessels for high performance PCR.

It also will ensure that Finnzymes Instruments can offer a broad range of innovative consumables to the molecular diagnostics and life science research markets.” Bruce Turner, current President of Bridge Biosciences, will take the helm of BioInnovations and says he “looks to offer consumable products with useful and novel features for researchers in the life science market.” The financial terms of the deal were not disclosed.

>>> Discuss This Story


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->